MK0767 and Sulfonylurea Combination Study - Full Text View

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00543491

Purpose

This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition	Intervention	Phase
Diabetes Mellitus, Type 2	Drug: MK0767	Phase III

MedlinePlus related topics: Diabetes

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Further study details as provided by Merck:

Study Start Date:	January 2003
Study Completion Date:	October 2004

Eligibility

Ages Eligible for Study:	21 Years to 78 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 Diabetes with inadequate glycemic control
On Sulfonylurea monotherapy
Male or non-pregnant Females
Age 21 to 78 years, inclusive
On a stable dose of sulfonylurea for at least 2 weeks prior to Visit 2/Week-6

Exclusion Criteria:

History of Type 1 diabetes
Patient is currently on insulin (monotherapy or in combination with oral agent), Rosiglitazone or pioglitazone or other PPAR-y agonists, Metformin agents
Patients with history of or intolerance of PPAR-y agonists

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00543491

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Study ID Numbers:	2007_629
Study First Received:	October 5, 2007
Last Updated:	October 12, 2007
ClinicalTrials.gov Identifier:	NCT00543491
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases

Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on January 15, 2009